vitalitiRX
loading
Every batch HPLC-verified ≥98%. Lot-traceable end to end.
Peptides are produced via solid-phase synthesis at a single GMP-aligned partner facility. Every production run is tied to a unique lot code from the first coupling step onward.
Independent third-party laboratories run HPLC purity analysis on every batch. Mass spec confirms peptide identity; a batch ships only if it clears ≥98% purity.
2–8°C, light-shielded, lot-segregated. Storage logs are reviewed weekly. Lyophilized vials remain shielded from light and humidity until they leave the facility. We do not consolidate batches under a single COA.
Discreet outer packaging. Every vial is labelled with its lot code and expiration date. Tracking is sent on label print.
Solid-phase synthesis produces a target peptide plus a long tail of byproducts — truncated sequences, deletion fragments, oxidised residues, residual coupling reagents. The 98% threshold caps these impurities at no more than 2% of the final product by mass. Anything below that, and the impurity profile becomes the dominant story. Anything above 98% and the marginal cost of additional purification stops buying meaningful identity. 98% is the industry-accepted ceiling where verified purity starts to mean something consistent across labs.
Every lot ships with an independent Certificate of Analysis on file. Below is the format your lot's COA arrives in — HPLC chromatogram, identity, the works. Request the document for the exact lot you receive.